Cyfuse Biomedical K.K.

4892.T
Drug Manufacturers - Specialty & Generic
2026/11/20 20:23 Updated
Market Cap: $31.0M (¥4.9B)
Stock Price: $3.07 (¥487)
Exchange Rate: 1 USD = ¥158.73

Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University — Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis

In joint research with Keio University and Fujita Health University, a platform technology for a novel osteochondral regeneration therapy for idiopathic medial femoral condyle osteonecrosis was developed using a bio 3D printer. An investigator-initiated clinical trial to evaluate the safety and efficacy of the investigational product KCF-BC1 will commence. The trial will be conducted at Keio University Hospital. Impact on financial results is currently being evaluated.

Importance:
Page Updated: November 18, 2026
IR Disclosure Date: November 18, 2026

Key Figures

  • Investigational product name: KCF-BC1 (osteochondral plug)
  • Indication: Idiopathic medial femoral condyle osteonecrosis
  • Planned start of clinical trial: To begin at Keio University Hospital

AI要約

Overview of New Technology and Start of Clinical Trial

In joint research with the Department of Orthopaedic Surgery at Keio University School of Medicine and Fujita Health University, Cyfuse Biomedical K.K. developed an osteochondral plug (KCF-BC1) that simultaneously regenerates superficial cartilage and deep subchondral bone using adipose-derived mesenchymal stromal cells and bio 3D printer technology. The scaffold-free approach is expected to reduce the risk of foreign body reactions. An investigator-initiated clinical trial using this product will commence.

Future Plans and Social Significance

This technology aims for regulatory approval in Japan as a regenerative medicine product and will be advanced toward commercialization and international expansion through public-private-academic collaboration. In the long term, it may contribute to extending healthy life expectancy in an aging society by enabling biological regeneration and reducing reliance on implants.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Cyfuse Biomedical K.K.

Company overview · Stock price · Financial data · All IR

View company page →